Administration of desmopressin (dDAVP), a potent and selective V2R agonist peptide, helps to differentiate between central diabetes insipidus (impaired AVP secretion) and nephrogenic diabetes insipidus. This evidence concerns the gene AVP and Central diabetes insipidus.